BiomX, Inc. (PHGE)
| Market Cap | 155.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.55M |
| Shares Out | 23.15M |
| EPS (ttm) | -4.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $6.71 |
| Previous Close | $6.69 |
| Change ($) | 0.02 |
| Change (%) | 0.30% |
| Day's Open | 6.58 |
| Day's Range | 6.61 - 6.80 |
| Day's Volume | 9,051 |
| 52-Week Range | 4.71 - 10.44 |
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today ...
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, toda...
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, toda...
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, toda...
BiomX is focused on large market opportunities using the unique approach of manipulating the microbiome utilizing phage therapy.
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2020 Results - Earnings Call Transcript
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today reporte...
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today an...
Forget traditional IPOs! This blank check vehicle is proving to be an effective tool for biotech companies to raise capital.
About PHGE
BiomX, a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targe... [Read more...]
| Industry Biotechnology | Founded 2015 |
| CEO Jonathan Eitan Solomon MBA | Employees 73 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol PHGE |